In the assessment of 12-month price targets, analysts unveil insights for Alnylam Pharmaceuticals, presenting an average target of $420.41, a high estimate of $570.00, and a low estimate of $333.00.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $406.0, a high ...

Fintel reports that on August 4, 2025, Oppenheimer upgraded their outlook for Alnylam Pharmaceuticals (NasdaqGS:ALNY) from ...

Fintel reports that on August 4, 2025, Wolfe Research upgraded their outlook for Alnylam Pharmaceuticals (NasdaqGS:ALNY) from ...

Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) shareholders will have a reason to smile today, with the analysts ...

With the business potentially at an important milestone, we thought we'd take a closer look at Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) future prospects. Alnylam Pharmaceuticals, Inc. discovers, ...

Alnylam Pharmaceuticals, Inc. shares soar with strong Q2 results, driven by Amvuttra's stellar U.S. launch for ATTR ...

Good morning, ladies and gentlemen, and welcome to the Alnylam Q2 2025 Earnings Conference Call. [Operator Instructions] This call is being recorded on Thursday, July 31, 2025. I would now like to ...

A stellar launch of rare heart disease med Amvuttra has boosted Alnylam’s market cap above $50 billion. | A stellar launch of ...

The better-than-expected launch of a rare heart disease drug pushed Alnylam (Nasdaq: ALNY) past the $50 billion market ...

Onpattro is the first approved RNA interference therapy. In addition to first-mover advantage, Alnylam is positioned to expand its reach in ATTR amyloidosis with next-generation Amvuttra, which is ...

Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $66.3 million in its second quarter.